About Rui Laboratories Private Limited
Data last updated: 17 December 2025
Rui Laboratories Private Limited is a private limited company based in Rambilli Mandal, Andhra Pradesh, India, recognised as a startup by DPIIT. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 16 November 2017, the company has been in operation for over 9 years.
Registered with ROC Vijayawada under CIN U24100AP2017PTC111480.
Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹29.62 Cr. It is led by directors including Vivekananda Reddy Mandala and Sitarama Krishna Reddy Kolli.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Plot No. 4J & 4K Denotified Area Apiic Industrial Area Atchutapuram, Rambilli Mandal, Andhra Pradesh, India – 531011.
As per the financials filed for FY 2023, the company reported a revenue of ₹42.65 Cr, a growth of 36.04% compared to the previous year.
The company has a workforce of approximately 117 employees as per the latest available data.
The company is associated with 1 brand - Rui Laboratories. As per MCA filings, the company has open charges of ₹24.27 Cr and satisfied charges of ₹82.13 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ruilaboratories.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressPlot No. 4J & 4K Denotified Area Apiic Industrial Area Atchutapuram, Rambilli Mandal, Andhra Pradesh, India – 531011
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Rui Laboratories Private Limited
Rui Laboratories Private Limited has one previous CIN (Corporate Identification Number): U24100TG2017PTC120673. The current CIN is U24100AP2017PTC111480, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100AP2017PTC111480 | Current |
| U24100TG2017PTC120673 | Previous |
Associated Brands with Rui Laboratories Private Limited
Rui Laboratories Private Limited operates one associated brand: Rui Laboratories. These brands represent Rui Laboratories Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures pharmaceutical intermediates and APIs for national and international customers. | ruilaboratories.com |
Competitors & Alternatives of Rui Laboratories Private Limited
Brands and companies operating in the same space as Rui Laboratories Private Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Rui Laboratories Private Limited
Rui Laboratories Private Limited operates primarily in the manufacturing sector. The company has 1 registered business activity segment, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| ********* | Manufacturing | ********* | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Rui Laboratories Private Limited
Rui Laboratories Private Limited is audited by MSPR & Co for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| MSPR & Co | blur-value | blur-value | blur-value |
Board of Directors of Rui Laboratories Private Limited
Rui Laboratories Private Limited is currently managed by 12 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Vivekananda Reddy Mandala
Also directs:
Krishnaveni Constructions Private Limited
|
Director | 10 Oct 2018 | 7 Years 9 Months | Current |
| Sitarama Krishna Reddy Kolli | Director | 16 Nov 2017 | 8 Years 7 Months | Current |
| Saritha Kesari | Director | 26 Jul 2024 | 1 Years 11 Months | Current |
| Rishika Kesari | Director | 26 Jul 2024 | 1 Years 11 Months | Current |
| Dileep Kumar Bayyana | Director | 27 Dec 2024 | 1 Years 6 Months | Current |
|
Narasimha Reddy Goli
Also directs:
Leenar Life Sciences Private Limited
|
Director | 26 Jul 2024 | 1 Years 11 Months | Current |
Financials of Rui Laboratories Private Limited FY 2024 filings available
Rui Laboratories Private Limited reported revenue of ₹42.59 Cr (up 36.04% YoY) for FY 2023. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Rui Laboratories Private Limited
As of FY 2023, Rui Laboratories Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Rui Laboratories Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Nov 2024 | Others | ₹97.21 Lakh | Open |
| 30 May 2024 | Others | ₹23.3 Cr | Open |
| 29 Sep 2021 | Hdfc Bank Limited | ₹48.82 Cr | Satisfied |
| 22 Feb 2021 | Others | ₹2.75 Cr | Satisfied |
| 15 May 2019 | State Bank of India | ₹13.41 Cr | Satisfied |
Total charge records: 6 View all charges
Employees and EPFO Compliance at Rui Laboratories Private Limited
Rui Laboratories Private Limited has a workforce of 117 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Rui Laboratories Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Rui Laboratories Private Limited
GSTIN & GST Filing Data of Rui Laboratories Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Rui Laboratories Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Rui Laboratories Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Rui Laboratories Private Limited
MSME Payment Delays by Rui Laboratories Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Rui Laboratories Private Limited
Subsidiaries & Group Companies of Rui Laboratories Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Rui Laboratories Private Limited with ownership details.
MCA Filings & Documents of Rui Laboratories Private Limited
MCA Filings & Documents of Rui Laboratories Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Rui Laboratories Private Limited
Frequently Asked Questions about Rui Laboratories Private Limited
Rui Laboratories Private Limited is an active private limited company in the pharma sector based in Rambilli Mandal, Andhra Pradesh, India. It was incorporated on 16 November 2017 (9+ years old) and is registered under CIN U24100AP2017PTC111480. The company has 117 employees.
Rui Laboratories Private Limited reported revenue of ₹42.65 Cr for FY 2023 (up 36.04% YoY).
The current directors of Rui Laboratories Private Limited are:
The primary industry of Rui Laboratories Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes, Rui Laboratories Private Limited is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Rui Laboratories Private Limited can be reached at the registered office: Plot No. 4J & 4K Denotified Area Apiic Industrial Area Atchutapuram, Rambilli Mandal, Andhra Pradesh, India – 531011, or through the website ruilaboratories.com.